By the Editors
Evacetrapib, an experimental cholesterol ester transfer protein inhibitor, raises HDL cholesterol and lowers LDL cholesterol — but does not reduce risk for cardiovascular events — according to an industry-funded, phase 3 trial in the New England Journal of Medicine.
Dr. Harlan Krumholz, editor-in-chief of NEJM Journal Watch Cardiology, offers his take on the findings at the link below.
